Aptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest Down 30.8% in January

Aptevo Therapeutics Inc. (NASDAQ:APVO) was the target of a large drop in short interest during the month of January. As of January 30th, there was short interest totaling 152,186 shares, a drop of 30.8% from the January 15th total of 219,920 shares. Approximately 15.3% of the company’s shares are short sold. Based on an average trading volume of 72,754 shares, the short-interest ratio is currently 2.1 days. Based on an average trading volume of 72,754 shares, the short-interest ratio is currently 2.1 days. Approximately 15.3% of the company’s shares are short sold.

Analysts Set New Price Targets

Several research firms recently issued reports on APVO. Weiss Ratings reissued a “sell (e)” rating on shares of Aptevo Therapeutics in a research note on Monday, December 29th. Wall Street Zen cut Aptevo Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 17th. One analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold”.

Aptevo Therapeutics Price Performance

APVO stock opened at $6.71 on Friday. Aptevo Therapeutics has a 1 year low of $5.94 and a 1 year high of $1,439.96. The firm has a 50-day moving average of $11.55 and a 200 day moving average of $23.51. The company has a market cap of $6.71 million, a P/E ratio of 0.00 and a beta of 1.49.

Institutional Investors Weigh In On Aptevo Therapeutics

An institutional investor recently bought a new position in Aptevo Therapeutics stock. Birchview Capital LP bought a new position in Aptevo Therapeutics Inc. (NASDAQ:APVO) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 10,000 shares of the biotechnology company’s stock, valued at approximately $30,000. Birchview Capital LP owned approximately 1.32% of Aptevo Therapeutics at the end of the most recent quarter. Institutional investors own 8.06% of the company’s stock.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system.

The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life.